Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02563548 · ClinicalTrials.gov registry record · Phase 1

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

A Phase 1 study of Gastric Cancer and NSCLC, sponsored by Halozyme Therapeutics.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
20
Study locations

NCT02563548 is a Phase 1 study of Gastric Cancer and NSCLC that has completed, run by Halozyme Therapeutics. The registered enrollment target is 56 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02563548, a Phase 1 study of Gastric Cancer and NSCLC, has completed, sponsored by Halozyme Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).

Conditions Studied

Gastric Cancer NSCLC

Interventions

  • DRUG Pembrolizumab
  • DRUG PEGPH20

Study Locations (20)

California

  • California Cancer Associates for Research and Excellence - Encinitas - Encinitas
  • University of California San Diego - Moores Cancer Center - La Jolla
  • St. Joseph's Hospital - Orange
  • University of California - Davis - Sacramento
  • St. Joseph's Hospital - Santa Rosa
  • Innovative Clinical Research - Whittier

Florida

  • Holy Cross Hospitals - Fort Lauderdale
  • University of Miami/Sylvester Cancer Center - Miami
  • Cleveland Clinic Florida - Weston

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic, Scottsdale, Arizona - Scottsdale

Colorado

  • University of Colorado Denver University of Colorado Anschutz Medical Campus - Aurora

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2015-10-22
Est. Completion 2019-03-26
Phase Phase 1

Sponsor

Halozyme Therapeutics

31 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02563548

The ClinicalTrials.gov registry entry for NCT02563548 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT02563548 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT02563548 about?

NCT02563548 is a clinical study titled "A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors". This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).

What is the current status of trial NCT02563548?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-10-22. Estimated completion is 2019-03-26.

What conditions does trial NCT02563548 study?

This clinical trial studies the following conditions: Gastric Cancer, NSCLC.

What interventions are being tested in trial NCT02563548?

The interventions under investigation include: Pembrolizumab (DRUG), PEGPH20 (DRUG).

Who is sponsoring clinical trial NCT02563548?

This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02563548 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

NSCLC

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.